Patient Leaflet Updated 02-Jun-2026 | Eugia (UK) Limited
Thalidomide 50 mg hard Capsules
Thalidomide 50 mg capsules, hard
thalidomide
Thalidomide causes birth defects and foetal death. Do not take thalidomide if you are pregnant or could become pregnant. You must follow the contraception advice given to you by your doctor.
1. What Thalidomide is and what it is used for
2. What you need to know before you take Thalidomide
3. How to take Thalidomide
4. Possible side effects
5. How to store Thalidomide
6. Contents of the pack and other information
Thalidomide contains an active substance called thalidomide. This belongs to a group of medicines which affect how your immune system works.
Thalidomide is used with two other medicines called ‘melphalan’ and ‘prednisone’ to treat adults with a type of cancer called multiple myeloma. It is used in people who have recently been diagnosed and who have not been prescribed another medicine for their multiple myeloma before who are aged 65 years and over or aged less than 65 years who cannot be treated with high dose chemotherapy, which can be very difficult for the body to handle.
Multiple myeloma is a type of cancer which affects a certain type of white blood cell, called the plasma cell. These cells collect in the bone marrow and divide out of control. This can damage the bone and kidneys. Multiple myeloma generally cannot be cured. However, the signs and symptoms can be greatly reduced or disappear for a period of time. This is called a ‘remission’.
Thalidomide works by helping the body’s immune system and directly attacking the cancer. It works in a number of different ways:
You will have been given specific instructions by your doctor, particularly on the effects of thalidomide on unborn babies (outlined in the Thalidomide Pregnancy Prevention Programme).
You will have been given an educational brochure for patient by your doctor. Read it carefully and follow the related instructions.
If you do not fully understand these instructions, please ask your doctor to explain them again before you take thalidomide. See also further information in this section under “Warnings and precautions” and “Pregnancy and breast-feeding”.
Do not take Thalidomide if any of the above applies to you. If you are not sure, talk to your doctor or pharmacist before taking Thalidomide.
Talk to your doctor, pharmacist, or nurse before taking this medicine in the following situations.
For women taking Thalidomide
Before starting the treatment, you should ask your doctor if you are able to become pregnant, even if you think this is unlikely. Even if you do not have a menstrual bleeding following cancer therapy, you may become pregnant.
If you are able to become pregnant:
Your doctor will tell you what method of contraception to use.
If you can become pregnant, your doctor will record with each prescription that the necessary measures, as outlined above, have been taken.
For men taking Thalidomide
Thalidomide passes into semen. Therefore, do not have unprotected intercourse, even if you had a vasectomy.
For all patients
Talk to your doctor before taking Thalidomide if
Your thyroid function may be checked before you take thalidomide and monitored during treatment.
At any time during or after your treatment, tell your doctor or nurse immediately if you experience: blurred, loss of or double vision, difficulty speaking, weakness in an arm or a leg, a change in the way you walk or problems with your balance, persistent numbness, decreased sensation or loss of sensation, memory loss or confusion. These may all be symptoms of a serious and potentially fatal brain condition known as progressive multifocal leukoencephalopathy (PML). If you had these symptoms prior to treatment with Thalidomide, tell your doctor about any change in these symptoms.
Your doctor may check if you have a high total amount of tumour throughout the body, including your bone marrow. This could lead to a condition where the tumours break down and cause unusual levels of chemicals in the body which can lead to kidneys failure (this condition is called Tumour Lysis Syndrome) (see also section 4 “Possible side effects”).
Your doctor should evaluate if you develop additional types of haematological malignancies (called acute myeloid leukaemia and myelodysplastic syndromes) during your treatment with Thalidomide (see also section 4 “Possible side effects”). You must not donate blood during Thalidomide treatment and for at least 7 days after stopping treatment.
If you are not sure if any of the above apply to you, talk to your doctor before taking Thalidomide.
Thalidomide is not recommended for use in children and young people under 18 years.
Tell your doctor or pharmacist if you are taking or have recently taken any other medicines.
This includes medicines obtained without a prescription, including herbal medicines.
Make sure you tell your doctor if you are taking any medicines which:
Do not drink alcohol while you are taking Thalidomide. This is because alcohol can make you sleepy and Thalidomide can make you even sleepier.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Pregnancy
Thalidomide causes severe birth defects or death to an unborn baby.
If you are pregnant, you must not take Thalidomide. In addition, you must not become pregnant while taking Thalidomide.
You must use one effective method of contraception if you are a woman who is able to become pregnant (see section 2, “What you need to know before you take Thalidomide”).
You must stop treatment and inform your doctor straight away if:
If you do become pregnant during the treatment with thalidomide, you must stop the treatment and inform your doctor immediately.
For men taking Thalidomide who have a female partner who is able to become pregnant, please see section 2 “What you need to know before you take Thalidomide”. If your partner becomes pregnant whilst you are taking thalidomide, you should inform your doctor immediately.
Breast-feeding
Do not breastfeed when taking Thalidomide as it is not known if thalidomide is passed into human breast milk.
Do not drive or use any tools or machines if you experience side effects, such as dizziness, tiredness, sleepiness or blurred vision.
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free’.
Always take Thalidomide exactly as your doctor or pharmacist has told you to. Check with your doctor or pharmacist if you are not sure.
The recommended dose is 200 mg (4 x 50 mg capsules) a day for adults aged 75 years and under or 100 mg (2 x 50 mg capsules) a day for adults aged over 75 years. However, your doctor will choose the dose for you, monitor your progress and may adjust your dose. Your doctor will tell you how to take Thalidomide and for how long you will need to take it (see section 2, “What you need to know before you take Thalidomide”).
Thalidomide is taken daily in treatment cycles, each cycle lasting 6 weeks, in combination with melphalan and prednisone which are taken on days 1 to 4 of each 6-week cycle.
To remove the capsule from the blister, press only one end of the capsule out to push it through the foil. Do not apply pressure on the centre of the capsule as this can cause it to break
If you take more Thalidomide than you should, talk to a doctor or go to a hospital straightaway. If possible, take the medicine pack and this leaflet with you.
If you forget to take Thalidomide at your regular time and
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
The following side effects may happen with this medicine:
It is important to note that a small number of patients with multiple myeloma may develop additional types of cancer, especially haematological malignancies, and it is possible that this risk may be increased with Thalidomide treatment; therefore, your doctor should carefully evaluate the benefit and risk when you are prescribed Thalidomide.
Very common (may affect more than 1 in 10 people)
Your doctor may monitor your blood cell counts during treatment with Thalidomide.
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Not known (frequency cannot be estimated from the available data):
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme, Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the wallet card and the blister after EXP. The expiry date refers to the last day of that month.
Do not use if you notice any damage or signs of tampering.
Clear PVC/Aclar(PCTFE) - Aluminium foil blister pack: “This medicinal product does not require any special storage conditions”
Clear PVC/PVdC - Aluminium foil blister pack: “Store below 30°C”.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.
Thalidomide capsules, hard are white colour powder filled in size “4” hard gelatin capsule with white opaque cap imprinted with “TLM” in black ink and white opaque body imprinted with “50” in black ink. Each capsule measures approximately 14.00 mm x 5.30 mm
Thalidomide 50 mg Capsules, Hard are available in blister pack (i.e., Clear PVC/Aclar (PCTFE) - Aluminium foil blister & Clear PVC/PVdC - Aluminium foil blister).
Pack size: 28 hard capsules
or
or
This leaflet was last revised in 02/2026.
Ref: Ver 2.0
P1541920
1 Roundwood Avenue, Stockley Park, Uxbridge, UB11 1AF, UK
+44 (0)208 845 8795
+44 (0)208 845 8795
+44 (0)208 845 8811
+44 (0)208 845 8811
+44 (0)208 845 8811
www.eugiapharma.com